March 2021 Awareness Night 25 YEARS IN PROSTATE CANCER CARE: Where we were and where we are headed Dr. Gerard Morton, MD, FRCPC Sunnybrook Health Science Centre CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation time is 1:19:39 <
The most impactful week in the movement to end prostate cancer! The annual Summit is a meeting that connects patients, caregivers, and some of the leading educators, researchers, and thought leaders in the prostate cancer community. The ZERO Summit was virtual in 2021, full of informative session presentations, and downloadable educational materials. Visit their website for videos of presentations and more.
January 2021 Awareness Night Treatment of Advanced Prostate Cancer: From A(palutamide) to Z(ytiga(tm)) Dr. Urban Emmenegger, MD Medical Oncologist, Odette Cancer Centre (Div. of Medical Oncology) and Sunnybrook Research Institute (Biological Sciences Platform) Assistant Professor, Dept. of Medicine, U. of Toronto Associate Member, Inst. of Medical Science, U. of Toronto CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation time is 2:15:05 <
Regular prostate cancer support meetings are held by various groups in Ontario and other provinces. Here is a partial list of when they occur and links to get more information: 1st Tuesday Date Speaker Topic/Subject First Tuesday Prostate Cancer Support Toronto website Third Tuesday Prostate Cancer Support Toronto website Fourth Tuesday Burlington
Awareness: The Prostate Cancer Support Toronto and Side by Side Prostate Cancer Support Groups Newsletter. In this Issue: Covid times PCC/CCS amalgamation Apology to Bill Mandel Phil Segal steps down Jan. Awareness Night – Dr. Urban Emmenegger – via Zoom North York Harvest Food Bank Thank you to our sponsors Support group update Awareness Newsletter celebrating 20 years Ask the health team – Dr. Dean Elterman Year-End Message from the Co-chairs On going projects and general information Read it by clicking the link below to open the pdf file: Jan_2021_Newsletter
Europa Uomo’s unique study examining quality of life after treatment for prostate cancer You can read about our EUPROMS study and download the whole EUPROMS presentation at here. Specific sections can be accessed by click on them below: General findings about quality of life Findings about discomfort, tiredness and insomnia Findings about mental health Findings about sexual function Findings about urinary incontinence Key messages
Abstract Objectives Limited data are available concerning the extent to which the initial prostate-specific antigen (PSA) measurement in men younger than age 60 predicts for the risk of prostate cancer (CaP) and how this compares to other known risk factors. Methods From 1991 to 2001, 13,943 men younger than 60 years old participated in a CaP screening study. Men aged 40 to 49 years were eligible for the study if they had a positive family history or African-American heritage, and men older than 50 years were screened without respect to risk factors. The CaP detection rate, PSA velocity, pathologic features, …
The PSA test is the best way to detect prostate cancer at an early stage when there are more treatment options and the chance of survival is the highest. Read the Canadian Cancer Society’s recommendations here. This is an update from previous positions. It was possibly brought about by the merger with Prostate Cancer Canada.